Trials / Available
AvailableNCT04586062
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Kedrion S.p.A. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Plasminogen | Human Plasminogen |
Timeline
- First posted
- 2020-10-14
- Last updated
- 2023-10-05
Source: ClinicalTrials.gov record NCT04586062. Inclusion in this directory is not an endorsement.